Alumis Announces Late-Breaker Psoriasis Presentation of 52-week Phase 2 OLE Data for ESK-001 at 2025 American Academy of Dermatology Annual Meeting and Accelerated Topline Phase 3 Data Readout
Portfolio Pulse from
Alumis Inc. will present 52-week Phase 2 data for its psoriasis treatment ESK-001 at the 2025 American Academy of Dermatology meeting. The company also announced that Phase 3 topline data is expected in Q1 2026.
February 28, 2025 | 2:30 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Alumis Inc. will present significant Phase 2 data for its psoriasis treatment ESK-001 at the 2025 AAD meeting, with Phase 3 data expected in Q1 2026. This could impact investor sentiment positively.
The announcement of Phase 2 data presentation and the timeline for Phase 3 data are significant milestones for Alumis. These updates could boost investor confidence and positively impact the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100